Skip to content

Evaluation of a training and communication-network nephrology program for community pharmacists

Development and impact of PROFIL ("Programme de Formation et de Liaison"), a training and communication network program for community pharmacists, on the clinical follow-up of moderate to severe chronic renal insufficiency patients: a cluster randomized controlled trial

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12610000613000
Acronym
PROFIL
Enrollment
90
Registered
2010-07-28
Start date
2004-09-01
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The purpose of this study is to evaluate the impact of a training and communication network program (PROFIL) on the management of drug related problems in chronic kidney disease patients recruited in a predialysis clinic. Compared to the usual care, PROFIL pharmacists were expected to issue more advices regarding pharmaceutical care to treating physicians.

Interventions

ProFiL (Programme de Formation et de Liaison) is a training and communication-network program designed to facilitate pharmaceutical care by community pharmacists. It comprises: 1) a training workshop; 2) a communication network to facilitate transfer of clinical information between a predialysis clinic and community pharmacies; and 3) a consultation service by hospital pharmacists with nephrology expertise. Between September and November 2004, all Laval (Canada) community pharmacies were asked

ProFiL (Programme de Formation et de Liaison) is a training and communication-network program designed to facilitate pharmaceutical care by community pharmacists. It comprises: 1) a training workshop; 2) a communication network to facilitate transfer of clinical information between a predialysis clinic and community pharmacies; and 3) a consultation service by hospital pharmacists with nephrology expertise. Between September and November 2004, all Laval (Canada) community pharmacies were asked to participate and randomly assigned to the ProFiL or usual-care (UC) group. ProFiL pharmacists attended a training workshop in November or December 2004. Patients of participating pharmacies attending a predialysis clinic were recruited between January and May 2005 and evaluated at baseline and six months. A three-hour workshop was developed by pharmacists and nephrologists. The objectives were to: 1) update basic knowledge on drug therapy in CKD to facilitate detection, prevention and management of DRPs; 2) familiarize pharmacists with ProFiL; 3) review administrative rules governing pharmaceutical opinions; and 4) meet the predialysis health care professionals. The workshop was offered on three occasions in November 2004 and December 2004. Pharmacists received 5.4 continuing education credits from the Quebec Order of Pharmacists. By the end of the workshop, it was expected that pharmacists would be able to: 1) identify nephrotoxic medications and propose alternatives to avoid their use; 2) adjust medication dosage in CKD; 3) write a pharmaceutical opinion; and 4) provide counselling on over-the-counter medications. The workshop included lecture presentations on: 1) clinical presentation of CKD (15 minutes) by a nephrologist; 2) management of DRPs in CKD (15 minutes) by a hospital pharmacist with expertise in nephrology; 3) writing of pharmaceutical opinions (15 minutes) by a community pharmacist; and 4) presentation of the ProFiL clinical tools (10 minutes by a pharmacist, including medication dosage adjustment tables for prescribed medications, over-the-counter medications and natural products. Two case studies (60 minutes) on the management of moderate and severe CKD were discussed in group of three or four pharmacists and within the entire group. Pharmacists had to use the information provided on the ProFiL clinical tools to identify DRPs and write a pharmaceutical opinion. If needed pharmacists responsible for the consultation service were available to answer questions.

Sponsors

Pfizer Canada
Lead SponsorCommercial sector/Industry

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Educational / counselling / training
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1) The patient is a regular customer at one of the participating community pharmacies; 2) Is attending the study pre-dialysis clinic; 3) Is at least 18 years of age; 4) Is covered by the Regie de l'assurance maladie du Quebec (RAMQ) with regard to his/her drugs for the entire duration of the study (employment insurance recipient, person aged 65 or older or member) and at least six months prior to study entry; 5) Agrees to use his/her usual community pharmacy for the entire duration of the study (six months); 6) Speaks and reads French; 7) Agrees to participate in the study and has signed the consent form.

Exclusion criteria

1) Unable to speak and read French andEnglish; 2) Unable to follow the study requirement

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026